BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is an international randomized trial evaluating the efficacy and safety of exemestane, alone or following tamoxifen. The large number of patients already recruited offered the opportunity to explore locoregional treatment practices between countries. METHODS:Patients were enrolled in Belgium, France, Germany, Greece, Ireland, Japan, the Netherlands, the UK and the USA. The core protocol had minor differences in eligibility criteria between countries, reflecting variations in national guidelines and practice regarding adjuvant endocrine therapy. RESULTS:Between 2001 and 2006, 9779 patients of mean(s.d.) age 64(9) years were randomized. Some 58.4 per cent had T1 tumours (range between countries 36.8-75.9 per cent; P < 0.001) and 47.3 per cent were axillary node positive (range 25.9-84.6 per cent; P < 0.001). Independent factors for type of breast surgery were country, age, tumour status and calendar year of surgery. After breast-conserving surgery, radiotherapy was given to 93.2 per cent of patients, 86.0 per cent in the USA and 100 per cent in France. Axillary lymph node dissection was performed in 82.0 (range 74.6-99.1) per cent. CONCLUSION: Despite international consensus guidelines, wide global variations were observed in treatment practices of early breast cancer. There should be further efforts to optimize locoregional treatment for breast cancer worldwide. Copyright 2010 British Journal of Surgery Society Ltd.
RCT Entities:
BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is an international randomized trial evaluating the efficacy and safety of exemestane, alone or following tamoxifen. The large number of patients already recruited offered the opportunity to explore locoregional treatment practices between countries. METHODS:Patients were enrolled in Belgium, France, Germany, Greece, Ireland, Japan, the Netherlands, the UK and the USA. The core protocol had minor differences in eligibility criteria between countries, reflecting variations in national guidelines and practice regarding adjuvant endocrine therapy. RESULTS: Between 2001 and 2006, 9779 patients of mean(s.d.) age 64(9) years were randomized. Some 58.4 per cent had T1 tumours (range between countries 36.8-75.9 per cent; P < 0.001) and 47.3 per cent were axillary node positive (range 25.9-84.6 per cent; P < 0.001). Independent factors for type of breast surgery were country, age, tumour status and calendar year of surgery. After breast-conserving surgery, radiotherapy was given to 93.2 per cent of patients, 86.0 per cent in the USA and 100 per cent in France. Axillary lymph node dissection was performed in 82.0 (range 74.6-99.1) per cent. CONCLUSION: Despite international consensus guidelines, wide global variations were observed in treatment practices of early breast cancer. There should be further efforts to optimize locoregional treatment for breast cancer worldwide. Copyright 2010 British Journal of Surgery Society Ltd.
Authors: Willemien van de Water; Esther Bastiaannet; Elysée T M Hille; Elma M Meershoek-Klein Kranenbarg; Hein Putter; Caroline M Seynaeve; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Gerrit-Jan Liefers; Cornelis J H van de Velde Journal: Oncologist Date: 2011-12-30
Authors: Peyman Hadji; Lina Asmar; Johanna G H van Nes; Thomas Menschik; Annette Hasenburg; Joachim Kuck; Johan W R Nortier; Cornelis J H van de Velde; Stephen E Jones; May Ziller Journal: J Cancer Res Clin Oncol Date: 2010-12-18 Impact factor: 4.553
Authors: Willemien van de Water; Caroline Seynaeve; Esther Bastiaannet; Christos Markopoulos; Steve E Jones; Daniel Rea; Annette Hasenburg; Hein Putter; Elysée T M Hille; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Cornelis J H van de Velde; Gerrit-Jan Liefers Journal: Oncologist Date: 2012-12-20
Authors: Iain S Whitaker; Maria Karavias; Ramin Shayan; Cara Michelle le Roux; Warren M Rozen; Russell J Corlett; G Ian Taylor; Mark W Ashton Journal: PLoS One Date: 2012-05-09 Impact factor: 3.240
Authors: M Kiderlen; E Bastiaannet; P M Walsh; N L Keating; S Schrodi; J Engel; W van de Water; S M Ess; L van Eycken; A Miranda; L de Munck; C J H van de Velde; A J M de Craen; G J Liefers Journal: Breast Cancer Res Treat Date: 2011-11-27 Impact factor: 4.872
Authors: Mandy Kiderlen; Paul M Walsh; Esther Bastiaannet; Maria B Kelly; Riccardo A Audisio; Petra G Boelens; Chris Brown; Olaf M Dekkers; Anton J M de Craen; Cornelis J H van de Velde; Gerrit-Jan Liefers Journal: PLoS One Date: 2015-02-03 Impact factor: 3.240
Authors: Josep M Escribà; Laura Pareja; Laura Esteban; Jordi Gálvez; Angels Melià; Laura Roca; Ramon Clèries; Xavier Sanz; Montse Bustins; María J Pla; Miguel J Gil; Josep M Borrás; Josepa Ribes Journal: BMC Res Notes Date: 2014-09-01